Literature DB >> 23825904

Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras.

Nahed Baddour1, Ebtehal Farrag, Ahmed Zeid, Essam Bedewy, Yousry Taher.   

Abstract

OBJECTIVE AND
BACKGROUND: Although p21 ras has been reported to be upregulated in hepatocellular carcinoma complicating chronic hepatitis C type I, p21 ras has a different role in advanced stages, as it has been found to be downregulated. The goal of this study was to investigate the status of p21 ras in early-stage/low-grade and late-stage/high-grade hepatocellular carcinoma and its possible link to apoptosis.
MATERIAL AND METHODS: Thirty-five cases each of chronic HCV hepatitis type 4 (group I) and cirrhosis with hepatocellular carcinoma (HCC) complicating chronic HCV hepatitis (groups II and III) were immunohistochemically evaluated using a p21 ras polyclonal antibody. The apoptotic index was determined in histologic sections using the terminal deoxynucleotidyl transferase-mediated d-UTP biotin nick end labeling (TUNEL) assay.
RESULTS: Significant differences (P=0.001) were detected in p21 ras protein expression between the three groups. A near 2-fold increase in p21 ras staining was observed in the cirrhotic cases compared to the hepatitis cases, and p21 ras expression was decreased in the HCC group. p21 ras expression correlated with stage (r=0.64, P=0.001) and grade (r=(-)0.65, P=0.001) in the HCC group and grade in the HCV group (r=0.44, P=0.008). Both p21 ras expression and TUNEL-LI were significantly lower in large HCCs compared to small HCCs (P=0.01 each). The TUNEL values were negatively correlated with stage in the HCC group (r=(-)0.85, P=0.001). The TUNEL values were also negatively correlated with grade in both the HCV and HCC groups (r=0.89, P=0.001 and r=(-)0.53, P=0.001, respectively). The p21 ras scores were significantly correlated with the TUNEL-LI values in the HCC group (r=0.63, P=0.001) and HCV group (r=0.88, P=0.001).
CONCLUSIONS: p21 ras acts as an initiator in HCC complicating type 4 chronic HCV and is downregulated with HCC progression, which most likely promotes tumor cell survival because it facilitates the downregulation of apoptosis with tumor progression.

Entities:  

Keywords:  HCV type 4; apoptosis; hepatocellular carcinoma; p21 ras; terminal deoxynucleotidyl transferase-mediated d-UTP biotin nick end labeling (TUNEL)

Year:  2013        PMID: 23825904      PMCID: PMC3696717          DOI: 10.3978/j.issn.1000-9604.2013.04.02

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  37 in total

1.  Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray.

Authors:  Eun Jung Chung; Young Kwan Sung; Mohammad Farooq; Younghee Kim; Sanguk Im; Won Young Tak; Yoon Jin Hwang; Yang Il Kim; Hyung Soo Han; Jung-Chul Kim; Moon Kyu Kim
Journal:  Mol Cells       Date:  2002-12-31       Impact factor: 5.034

Review 2.  Comparative and integrative functional genomics of HCC.

Authors:  J-S Lee; S S Thorgeirsson
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

3.  Molecular classification of hepatocellular carcinoma.

Authors:  Jessica Zucman-Rossi
Journal:  Dig Liver Dis       Date:  2010-07       Impact factor: 4.088

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Genomic aberrations in human hepatocellular carcinomas of differing etiologies.

Authors:  N Wong; P Lai; E Pang; L F Fung; Z Sheng; V Wong; W Wang; Y Hayashi; E Perlman; S Yuna; J W Lau; P J Johnson
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

6.  Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC.

Authors:  K Kenmochi; S Sugihara; M Kojiro
Journal:  Liver       Date:  1987-02

7.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

8.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

9.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

10.  Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.

Authors:  Abdel Rahman N Zekri; Hanaa M Alam El-Din; Abeer A Bahnassy; Mohsen M Khaled; Ashraf Omar; Inas Fouad; Mahmoud El-Hefnewi; Fouad Thakeb; Mostafa El-Awady
Journal:  Virol J       Date:  2007-02-14       Impact factor: 4.099

View more
  2 in total

1.  [Expressions of ΔNp63α, DPC4/Smad4 and P21 in cervical squamous cell carcinoma an their clinical significance].

Authors:  Wenqing Song; Tingting Huang; Lan Yu; Zenong Cheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

Review 2.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.